| Literature DB >> 32360553 |
Andrew Hendrick1, Jesse Smith2, Chris Stelton2, Scott Barb2, Jiong Yan2, Blaine Cribbs2, Nieraj Jain2, Steve Yeh2, G Baker Hubbard2, Li He2, Susov Dhakal2, P Michael Iuvone3.
Abstract
Animal studies suggest that the retinal dysfunction in diabetic subjects that precedes overt clinical vasculopathy may be due to a retinal dopamine deficit. We analyzed levels of dopamine (DA) and its primary metabolite, 3,4-dihydroxyphenylacetic acid (DOPAC), in the vitreous of diabetic and non-diabetic human subjects. Adult patients undergoing pars plana vitrectomy for non-hemorrhagic indications were prospectively recruited from the Emory Eye Center in Atlanta, GA. Vitreous samples were analyzed using high performance liquid chromatography (HPLC) to measure levels of DOPAC and DA in the vitreous specimens. Vitreous samples from 9 diabetic patients and 20 from non-diabetic patients were analyzed. No eyes had apparent diabetic retinopathy. Mean normalized DA concentration in vitreous of diabetic subjects was 0.76 ± 0.12 pg/μL vs. 0.73 ± 0.08 pg/μL in non-diabetic vitreous (p = 0.849). DOPAC concentration was 8.84 ± 0.74 pg/μL in vitreous of diabetic subjects vs. 9.22 ± 0.56 pg/μL in vitreous of non-diabetic subjects (p = 0.691). No difference was observed in the concentrations of DA and DOPAC in the vitreous of people without diabetes compared to those with diabetes without retinopathy.Entities:
Keywords: Diabetes; Diabetic retinopathy; Dopamine; Vitreous
Mesh：
Substances：
Year: 2020 PMID： 32360553 PMCID： PMC7282952 DOI： 10.1016/j.exer.2020.108040
Source DB: PubMed Journal: Exp Eye Res ISSN： 0014-4835 Impact factor: 3.467